The acquisition of Deep 6 AI by Tempus is likely to positively impact Tempus's stock price in the short term. The enhancement of AI-driven clinical trial matching capabilities is a strategic move that could lead to faster patient recruitment and advancements in precision medicine, making Tempus more competitive in the healthcare technology sector.